« Return to News | Drug Sponsors

Tioga raises $10 million for irritable bowel syndrome trial

Friday, April 13, 2012 01:26 PM

Tioga Pharmaceuticals of San Diego has closed its $10 million Series B equity financing led by new investor Thomas, McNerney & Partners, which invested $8 million in the round.

In connection with the financing, Jason Brown, Ph.D., principal at Thomas, McNerney & Partners, has joined Tioga's board of directors.  Existing investor Genesys Capital Partners also participated in the financing.

Tioga is currently conducting a phase III trial of its compound asimadoline for the treatment of diarrhea-predominant irritable bowel syndrome (D-IBS) under a special protocol assessment with the FDA. The 600-subject randomized, double-blind, placebo-controlled clinical trial is one of two registration trials required for approval in the U.S. Asimadoline has also been granted Fast Track designation by the FDA for the treatment of D-IBS.

"Tioga marks our third new investment in Southern California since we opened our San Diego office last year,” said Brown, “and is a great example of the continuing growth of life sciences in the region. Asimadoline is an attractive, novel, late-stage medicine that has the potential to fulfill the substantial unmet need in D-IBS.  It has demonstrated impressive efficacy in D-IBS patients, and an excellent safety profile in more than 1,100 subjects."  

In September 2009, Ono Pharmaceutical licensed exclusive rights from Tioga to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to the compound.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.